FULGENT GENETICS, INC. Payments for Repurchase of Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- FULGENT GENETICS, INC. payments for repurchase of equity for the quarter ending 2016-12-31 was $1.00K.
- FULGENT GENETICS, INC. payments for repurchase of equity for the quarter ending 2016-09-30 was -$1.00K.
- FULGENT GENETICS, INC. payments for repurchase of equity for fiscal 2016 was $11.98M.
| Period end | Payments for Repurchase of Equity 3 month | Payments for Repurchase of Equity 12 month |
|---|---|---|
| 2016-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $11.98M 10-K · filed 2018-03-20 |
| 2016-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |